CardioGenics Holdings Inc. (CGNH): opps ~ 3 of 8

Play Episode

5min

Proactive - Interviews for investors

Orion Minerals CEO on Prieska & Okiep DFS milestones as company enters next phase

Orion Minerals Ltd (ASX:ORN, JSE:ORN) managing director and CEO Errol Smart talked with Proactive's Stephen Gunnion about the completion of definitive feasibility studies (DFS) for both the company’s flagship Prieska copper-zinc project and the Flat Mines project at its Okiep copper project. Smart described this as a pivotal moment, noting, “It’s taken us eight years now to put them together… but it's really a great outcome for us.” The studies confirm robust development pathways for both operations in South Africa's Northern Cape, with both projects fully permitted and development-ready. Smart said Orion is in a unique position globally, with capital intensity figures below key industry benchmarks. The combined production profile is expected to deliver 30,000 tonnes of copper annually at around $9,500 per tonne capital intensity, placing the company in the lower quartile of the cost curve. The Prieska project will follow a two-phase development plan, with a modest $25 million start-up operation set to begin production within 13 months, followed by a ramp-up to full-scale output. Smart also confirmed that discussions are underway with strategic partners, including the Industrial Development Corporation and offtake-related financiers. He highlighted that smelters and traders are actively seeking long-term copper supply, saying, “We represent a very interesting opportunity for them, with certainty.” Visit Proactive’s YouTube channel for more company updates and interviews. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #OrionMinerals #CopperMining #PrieskaProject #OkiepProject #BaseMetals #MiningInvestment #FeasibilityStudy #SouthAfricaMining #CopperProduction #ZincProduction

Proactive - Interviews for investors

Quantum Base to list on AIM with £5M IPO plan

Quantum Base CEO Tom Taylor joined Stephen Gunnion in the Proactive studio with more about the company’s upcoming listing on the AIM market and its breakthrough anti-counterfeiting technology. Quantum Base, founded in 2013 as a spin-out from Lancaster University, has developed an atomic fingerprint that offers 100% secure authentication of goods, scannable with any smartphone. “It tells you 100% if something is real or it's fake,” Taylor said, describing the technology as a major leap in the fight against counterfeiting. Taylor explained that the technology has applications across sectors including brand protection, pharmaceuticals, tax stamps, banknotes, passports and even aerospace parts. The firm is already working with clients globally—from North America to the Middle East—and targeting both commercial brands and government organisations. The IPO is expected to raise £5 million, with £4.70 million already committed and trading set to begin on Friday under the ticker QUBE. The retail offer remains open. “We really want to grow… AIM really helps us grow,” Taylor said, noting the listing will support product development and expansion into new verticals. Key uses of the funds will include expanding Quantum Base’s commercial team and scaling its product reach into global markets. Looking ahead, Taylor said investors should watch for announcements of new customers and entry into new industries as milestones on the path to profitability. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications to stay updated. #QuantumBase #TomTaylor #AntiCounterfeiting #AtomicFingerprint #AIMListing #IPO2025 #SmartphoneSecurity #PharmaceuticalSecurity #BrandProtection #QuantumTech #QUBE #InvestmentNews #ProactiveInvestors

Proactive - Interviews for investors

2D Photonics CEO discusses plans to scale up advanced graphene-based photonics technology

Frontier IP Group portfolio company 2D Photonics CEO Ben Jensen talked with Proactive's Stephen Gunnion about the company’s recent €25 million funding round and its plans to scale up its advanced graphene-based photonics technology. Jensen explained the growing demand for faster, more cost-effective data transmission solutions, driven by sectors such as AI and 5G. “What’s required today is ever faster data transmission at lower costs,” he said. According to Jensen, the new device architecture 2D Photonics has developed simplifies photonics design while significantly improving performance. This innovation is crucial for enabling higher bandwidth and lower power consumption across data networks. The funding will support the expansion of the leadership team and the development of pilot production capabilities. Jensen emphasized the importance of execution at this early stage, noting that the goal is to demonstrate the scalability of the technology for semiconductor foundries and ultimately reach high-volume manufacturing. He also discussed future applications, pointing to sectors such as space and defence, where rugged environments make traditional photonics challenging. In addition, the technology has relevance for Advanced Driver-Assistance Systems (ADAS), where rapid data transmission between sensors is critical for vehicle safety. Visit Proactive’s YouTube channel for more insightful interviews like this. Don’t forget to like this video, subscribe to our channel, and enable notifications so you never miss an update. #GraphenePhotonics #2DPhotonics #FrontierIPGroup #DataTransmission #SemiconductorTech #ADAS #SpaceTech #PhotonicsInnovation #GrapheneTech #DeepTechStartups #HighSpeedData #BenJensen #ProactiveInvestors

Proactive - Interviews for investors

Allergy Therapeutics turns the corner, targets market launches

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive's Stephen Gunnion about the company’s financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control. Llobet highlighted that the company saw a 4% constant currency growth in euro-denominated sales—double that of the previous period—driven by improved supply chains and the strong performance of new and registered products. “The top line is good in terms of quantity and quality,” he said. Furlong added that these results, along with the recent financial restructuring, demonstrate a clear path to sustainable health. The company’s cash position rose to £21.7 million at the end of December from £12.9 million in June, aided by external funding and shareholder support. On the clinical side, Llobet described the Grass MATA MPL program as a potential “game changer”, with a Marketing Authorisation Application submitted in Germany. He also noted the progress of the Polyvac Peanut program, which aims to offer a short-course treatment capable of disease modification, differentiating it from current therapies. The company remains focused on progressing these pipeline assets while maintaining financial discipline. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay updated. #AllergyTherapeutics #BiotechNews #Immunotherapy #GrassMATA #PeanutAllergy #VaccineDevelopment #R&D #Pharmaceuticals #FinancialResults #InvestorUpdates #ProactiveInvestors

Followers	1170
Posts	174981
Boards Moderated	4
Alias Born	12/20/2003

Volume:	33,354
Day Range:	0.0001 - 0.0001
Bid:
Ask:
Last Trade Time:	12:31:00 PM EDT
Total Trades:	3

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

CGNH Detailed Quote

Recent CGNH News

More CGNH News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent CGNH News

Go Ad-Free